The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: Implications for 114mIn- mediated targeting therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 9, 2009, Pages 1460-1468

  Tolmachev, Vladimir ^a,b,c   Wållberg, Helena ^a   Andersson, Karl ^b,d   Wennborg, Anders ^a   Lundqvist, Hans ^b   Orlova, Anna ^a,b  

^a Affibody AB   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d Ridgeview Instruments AB   (Sweden)

Author keywords

114mIn; Affibody molecule; Albumin binding domain; Biodistribution; Radionuclide therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALBUMIN; BENZYL 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CHX A'' PENTETIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDIUM 111; INDIUM 114M; PENTETIC ACID; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON; FEMALE; HUMAN; HUMAN CELL; MICROMETASTASIS; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ALBUMINS; ANIMALS; CELL LINE, TUMOR; HUMANS; INDIUM RADIOISOTOPES; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; ORGANOMETALLIC COMPOUNDS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION;

EID: 68949202319     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1134-9     Document Type: Article

References (34)

1. DM Goldenberg 2003 Advancing role of radiolabeled antibodies in the therapy of cancer Cancer Immunol Immunother 52 281 296
2. M Jain G Venkatraman SK Batra 2007 Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation Clin Cancer Res 13 1374 1382
3. V Tolmachev A Orlova FY Nilsson J Feldwisch A Wennborg L Abrahmsén 2007 Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy Expert Opin Biol Ther 7 555 568
4. FY Nilsson V Tolmachev 2007 Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy Curr Opin Drug Discov Devel 10 167 175
5. A Orlova J Feldwisch L Abrahmsén V Tolmachev 2007 Update: affibody molecules for molecular imaging and therapy for cancer Cancer Biother Radiopharm 22 573 584
6. MA Fortin A Orlova PU Malmström V Tolmachev 2007 Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma Int J Mol Med 19 285 291
7. 177Lu-labeled HER2-specific Affibody molecule Cancer Res 67 2773 2782
8. 90Y Radiother Oncol 21 91 99
9. AI Kassis 2004 The amazing world of auger electrons Int J Radiat Biol 80 789 803
10. 90Y-labeled somatostatin analogs J Nucl Med 46 13S 17S
11. 114mIn via both DTPA and a macrocyclic chelator J Nucl Biol Med 36 33 40
12. V Tolmachev P Bernhardt E Forssell-Aronsson H Lundqvist 2000 114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-phe-octreotide Nucl Med Biol 27 183 188
13. EN Sabbah J Kadouche D Ellison C Finucane D Decaudin SJ Mather 2007 In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer Nucl Med Biol 34 293 304
14. S Froidevaux A Heppeler AN Eberle AM Meier M Häusler C Beglinger, et al 2000 Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy Endocrinology 141 3304 3312
15. MW Brechbiel 2008 Bifunctional chelates for metal nuclides Q J Nucl Med Mol Imaging 52 166 173
16. CA Boswell MW Brechbiel 2007 Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view Nucl Med Biol 34 757 778
17. A Orlova D Rosik M Sandström H Lundqvist L Einarsson V Tolmachev 2007 Evaluation of [(111/114m)In]-CHX-A″-DTPA-ZHER2:342, an affibody ligand conjugate for targeting of HER2-expressing malignant tumors Q J Nucl Med Mol Imaging 51 314 323
18. E Lundberg I Höidén-Guthenberg B Larsson M Uhlén T Gräslund 2007 Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples J Immunol Methods 319 53 63
19. A Orlova T Tran C Widström T Engfeldt A Eriksson Karlström V Tolmachev 2007 Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors Int J Mol Med 20 397 404
20. PA Schubiger R Alberto A Smith 1996 Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate Bioconjug Chem 7 165 179
21. FF Knapp Jr S Mirzadeh 1994 The continuing important role of radionuclide generator systems for nuclear medicine Eur J Nucl Med 21 1151 1165
22. E Horak F Hartmann K Garmestani C Wu M Brechbiel OA Gansow, et al 1997 Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1 J Nucl Med 38 1944 1950
23. 212Bi generator Nucl Med Biol 32 741 747
24. 212Pb-labeled radioimmunoconjugate targeting HER2 Cancer Biother Radiopharm 20 557 568
25. 225Ac radioimmunopharmaceuticals Appl Radiat Isot 57 841 847
26. 225Ac-HuM195, in nonhuman primates J Nucl Med 45 129 137
27. 227Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy Nucl Med Biol 33 271 279
28. 227Th Cancer Biother Radiopharm 22 469 479
29. 140Nd Acta Oncol 39 727 730
30. 111In Appl Radiat Isot 62 451 456
31. 134La, an Auger electron and positron-emitting generator for radionuclide therapy Phys Med Biol 47 615 629
32. JS Jaggi BJ Kappel MR McDevitt G Sgouros CD Flombaum C Cabassa, et al 2005 Efforts to control the errant products of a targeted in vivo generator Cancer Res 65 4888 4895
33. JS Jaggi SV Seshan MR McDevitt G Sgouros E Hyjek DA Scheinberg 2006 Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys Int J Radiat Oncol Biol Phys 64 1503 1512
34. A Orlova A Bruskin A Sjöström H Lundqvist L Gedda V Tolmachev 2000 Cellular processing of (125)I- and (111)In-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells Nucl Med Biol 27 827 835